Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
HTR3C	170572	CHEMBL1188853	CHEMBL1188853		TdgClinicalTrial
HTR3C	170572	DOLASETRON	CHEMBL2368925		TdgClinicalTrial
HTR3C	170572	PUMOSETRAG	CHEMBL1643880		TdgClinicalTrial
HTR3C	170572	TEDATIOXETINE	CHEMBL2104986	antagonist	ChemblInteractions
HTR3C	170572	GRANISETRON	CHEMBL289469		TdgClinicalTrial
HTR3C	170572	RG3487	CHEMBL3544952	antagonist	ChemblInteractions

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
HTR3C	rs6807362	GG	granisetron	efficacy	no	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Genotype GG is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes CC + CG.	29177570	1449170293
HTR3C	rs6766410	A	opioids	dosage	no	Variant had no significant association with opioid dose in either the development sample or the validation sample.	Allele A is not associated with dose of opioids in people with Pain as compared to allele C.	21398039	1449714449
HTR3C	rs6807362	C	opioids	dosage	no	Variant had no significant association with opioid dose in either the development sample or the validation sample.	Allele C is not associated with dose of opioids in people with Pain as compared to allele G.	21398039	1449714456
HTR3C	rs6808122	A	opioids	dosage	no	Variant had no significant association with opioid dose in either the development sample or the validation sample.	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.	21398039	1449714442
HTR3C	rs6807670	A	opioids	dosage	no	Variant had no significant association with opioid dose in either the development sample or the validation sample.	Allele A is not associated with dose of opioids in people with Pain as compared to allele G.	21398039	1449714463
HTR3C	rs6766410	CC	granisetron	efficacy	no	Patients with cancer, treated with cisplatin who had been treated with granisetron and palonsetron. Nausea and vomiting episodes were recorded for the first 120 h post cisplatin. With regard to vomiting events, presence/absence of symptoms and the time of onset were described. Nausea severity was categorized using a 4-point Likert scale (0 = no nausea, 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea) according to the subjective assessment of each patient.	Genotype CC is not associated with response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotypes AA + AC.	29177570	1449170281